Delisting riskPopularity #5,351Earnings are out
NCEL · NASDAQ · Biotechnology

NewcelX (NCEL)

Develops stem-cell-derived islet and astrocyte therapies for diabetes and ALS.

$2.85
vs last close−0.19 (−6.12%)

Something off on this page? Send us feedback.

EPSReportedEstimate

Jun '23Dec '23May '24Oct '24May '25Oct '25Feb '26Sep '26
Reported−$0.20−$68.00−$1.40−$1.94−$26.30−$10.50$1.29−$0.53
Estimate−$6.80−$68.00−$84.00−$0.53
Surprise+97.1%0.0%+98.3%0.0%

RevenueReportedEstimate

Jun '23Dec '23May '24Oct '24May '25Oct '25Feb '26Sep '26
Reported
Estimate
Surprise

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Mar 2027−$0.65
Sep 2026−$0.53−$0.530.0%
May 2026
Feb 2026$1.29
Oct 2025
Oct 2025−$10.50
May 2025−$26.30
Aug 2024
Oct 2024
May 2024
Dec 2023
Jun 2023
Mar 2023
May 2023
Oct 2022
Jun 2022
Mar 2022
Sep 2021
May 2021
Jun 2020
Dec 2019
Jun 2019
Dec 2018
Jun 2018
Jun 2017

The latest year is open to everyone — the 17 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Mar 3, 2027−$0.65
Sep 18, 2026−$0.53−$0.530.0%−6.8%
May 15, 2026
Feb 25, 2026$1.29−0.4%
Oct 6, 2025
Oct 4, 2025−$10.50−4.0%
May 16, 2025−$26.30+0.6%
Aug 28, 2024
Oct 18, 2024
May 15, 2024
Dec 6, 2023
Jun 30, 2023
Mar 23, 2023
May 5, 2023
Oct 11, 2022
Jun 30, 2022
Mar 24, 2022
Sep 28, 2021
May 14, 2021
Jun 30, 2020
Dec 31, 2019
Jun 30, 2019
Dec 31, 2018
Jun 30, 2018
Jun 30, 2017

The latest year is open to everyone — the 17 quarters behind it read with an account.